Phosphodiesterase inhibitors

409Citations
Citations of this article
382Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Phosphodiesterases are a diverse family of enzymes that hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messengers cAMP and cGMP, and hence cell function. Theophylline and papaverine have historically been used therapeutically and are known to be weak inhibitors of PDE, but to what extent this contributed toward their clinical efficacy was poorly defined. However, the discovery of 11 isoenzyme families and our increased understanding of their function at the cell and molecular level provides an impetus for the development of isoenzyme selective inhibitors for the treatment of various diseases. This review focuses on the development of PDE3 inhibitors for congestive heart failure, PDE4 inhibitors for inflammatory airways disease and most successfully, PDE5 inhibitors for erectile dysfunction. © 2006 Nature Publishing Group All rights reserved.

Cite

CITATION STYLE

APA

Boswell-Smith, V., Spina, D., & Page, C. P. (2006, January). Phosphodiesterase inhibitors. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0706495

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free